A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT00449033 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

904

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Bayer